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Prevalence and predictors of renal artery stenosis in hypertensive 
patients undergoing coronary angiography 
 
 
ABSTRACT: 
SETTING:Department of Cardiology, Government Rajaji Hospital, Madurai, 
Tamilnadu. 
OBJECTIVES: (i) To study 1) The prevalence of renal artery stenosis (RAS) 
in hypertensive patients with suspected coronary artery disease (CAD) 
undergoing coronary angigraphy by renal angiography. 2) Predictors of 
significant RAS. 3) Association between hypertension, CAD and RAS. 
DESIGN: Single centre cross section observational study. This study was 
conducted among 75 hypertensive patients who were admitted in our hospital 
with diagnosed CAD for coronary angiography since December 2013.After 
completion of CAG, renal angiography was done selectively using the same 
judkins right catheter which was used during cardiac catheterization. 
RESULTS: The mean age of the patients in our study is 59.5yrs.The  Male: 
Female ratio-1.8:1. The prevalence of Renal artery stenosis in our case is 20% 
(15/75). Unilateral RAS is 17.33% ( 13/15). Bilateral RAS is 2.66% (2/15).Age 
>55yrs,female sex, Stage II hypertension, resistant hypertension, duration of 
hypertension, multivessel disease and the presentation of heart failure are 
statistically significant predictors of RAS. The presence of angiographically 
documented  CAD patients were (71/75).Only 4 patients had normal coronaries 
and all the 4 patients did not have RAS. 
Conclusion: In our study the absolute number of patients is small. However the  
prevalence is significantly higher if hypertensive population with CAD is 
screened for ARAS. Female sex, elderly age, severe HT, triple vessel disease 
are significant association with ARAS. We recommend screening RAS in 
hypertensive CAD patients with high risk predictors. 
Keywords: CAD, RAS, CAG, renal angiography 
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INTRODUCTION 
 
 
Atherosclerotic renovascular disease is a frequently overlooked 
and potentially correctable disease. Unsuspected renal artery stenosis of 
varying severity coexists with coronary artery disease (CAD) patients. It 
is increasingly recognized that atherosclerotic renal artery stenosis 
(ARAS), accounting for about 90% of cases of renal artery stenosis is an 
important cause of renal insufficiency, refractory hypertension, and 
cardiac destabilization syndromes (unstable angina and flash pulmonary 
edema) 
The clinical entity Peripheral arterial disease (PAD) is used to 
define stenotic, occlusive, and aneurysmal diseases of the aorta and its 
branch arteries. The important point is that coronary arteries are not 
included in the definition.
1
 
The recommendation from American Heart Association scientific 
committee is that to screen high risk patients for renal artery stenosis as 
part of cardiac catheterization. These high risk patients are identified to 
be potential candidates of renal vascularization.
2
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The prevalence of renal artery stenosis (RAS) ranges from 3-30% 
in patients undergoing coronary angiography for suspected coronary 
artery disease. The prevalence of atherosclerotic RAS in Hypertensive 
patients undergoing coronary angiography is low, but substantially 
higher in patients with established peripheral (50%) and/or coronary 
artery disease (30%), and elderly population.
3
 
RAS coexists with CAD of varying severity. There is a linear 
correlation between RAS and severity of CAD. It independently predicts 
mortality in CAD patients undergoing CAG. The increased mortality is 
mainly attributed by cardiovascular diseases. The coexistence of 
Hypertension, Coronary artery Disease and renal artery stenosis forms a 
deadly combination. 
The indications for renal artery intervention are a matter of 
continuing controversy. It is no longer tenable to practice renal 
intervention indiscriminately. The real challenge is to identify high risk 
patients who would really benefit from revascularization. If the patient’s 
renal function remains stable over a period of 6-12 months and if the 
Hypertension is under control, then patient can be maintained with 
medical management. 
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The best recommendation is for bilateral significant RAS and 
cardiac destabilization syndromes. 
RAS accounts for 5% of all cases of Hypertension. Males are 
commonly affected than females. Population based studies showed 9% 
for males and 5% for females. When studied for coronary artery disease 
the incidence is 19%.when studied for peripheral disease the incidence 
is 35-50%. In half of the renal artery stenosis cases, bilateral disease is 
seen. Significant renal artery stenosis is when > 60% stenosis is seen. 
Over 5yrs the atherosclerotic plaque progress to complete occlusion in 
15 % of the case. Atherosclerosis shows predilection to origin of renal 
arteries. The age group affected is in the middle age and elderly.
4
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AIM 
 
Prevalence and predictors of renal artery stenosis in 
hypertensive patients undergoing coronary angiography 
To Study 
 The prevalence of renal artery stenosis (RAS) in hypertensive 
patients with suspected coronary artery disease (CAD), by 
renal angiography. 
 Predictors of significant RAS. 
 Association between hypertension, CAD and RAS. 
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REVIEW OF LITERATURE 
Atherosclerosis is a systemic disease. It involves multiple 
vascular beds. Atherosclerotic Renal Artery stenosis is a under 
recognized clinical entity. Its coexistence with coronary artery disease 
(CAD) and peripheral artery disease is increasing as the ageing 
population is increasing.
5 
ARAS has frequent association with 
Hypertension whether hypertension is a cause or consequence is still 
unresolved and unanswerable. It is also frequently associated with 
decreased renal function. The cardiovascular events are high in patients 
with renal artery stenosis and coexisting hypertension. Systemic 
Hypertension is found associated in unquantifiable numbers in ARAS. 
Secondly ARAS could be primary causative role for hypertension. The 
mechanisms are activation of renal angiotensin system, heightened 
sympathetic activity, oxidative stress, inflammation and fibrosis. The 
management of ARAS has only two options medical management and 
percutaneous transluminal renal angioplasty (PTRA). The Meta analysis 
assessed the cardiovascular events in patients with Hypertension and 
ARAS comparing drug versus PTRA. It concluded that PTRA has no 
superiority over medical therapy in preventing CV events, in reducing 
BP and improving renal function.
6
 But there are specific groups bilateral 
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RAS, unexplained pulmonary edema, refractory angina and resistant 
Hypertension where PTRA has a definite role although this subgroup is 
not individually studied.
7
 
Definitions: Hypertension: 
Hypertension is defined as values >140 mmHg SBP and/or 
>90mmHg DBP, based on the evidence from RCTs that in patients with 
these BP values treatment-induced BP reductions are beneficial.  
 
 
 
 
 
 
 
 
 
Definitions and Classification of office blood pressure levels (mmhg) 
Category Systolic  Diastolic 
Optimal <120 and <80 
Normal 120 - 129 and /or 80- 84 
High normal 130-139 and / or 85 – 89 
Grade – 1 Hypertension 140- 159 and/or 90-99 
Grade – 2 hypertension 160-  179 and/ or 100- 109 
Grade – 3 Hypertension <180 and /or <110 
Isolated Systolic Hypertension < 140 and <90 
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The above classification cannot be applied to children and 
adolescents. It has special recommendations based on special criteria. It 
is very well adopted in the young, middle age and elderly groups.
8 9
 
It is found that renal artery stenosis coexists in all stages of 
hypertension. The stenosis is hemodynamically significant, but it is 
more commonly recognized in patients with stage 2 or resistant 
hypertension.  As these are the individuals who are clinically suspected 
and carefully evaluated for additional problems. If both kidneys show 
evidence of bilateral renal artery stenosis then there is a greater threat to 
the viability of kidneys. It can lead to reduced kidney function leading to 
ischemic nephropathy. 
 
 
 
 
 
 
 
 
Changes in blood pressure classification 
JNC 6 category SBP/ DBP JNC 7 category 
Optimal <120 /80 Normal 
Normal 
Borderline 
120 – 129 /80 -84 
130 -139 / 85 -89 
Pre hypertension 
Hypertension >140 /90 Hypertension 
Stage 1 
Stage 2 
Stage 3 
140 -159 / 90- 99 
160 – 179 / 100-109 
>180 /110 
Stage 1 
Stage 2 
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ARAS 
Atherosclerotic Renal Artery Stenosis:  
The criteria established to define RAS are 
1) Renal angiographic stenosis ≥ 60% and < 100%  
2) Systolic velocity of >300 cm/sec in duplex ultrasonography   
3) Core lab approved MRA  
4) Core lab approved CTA 
Significant atherosclerotic RAS (ARAS), defined as a decrease of 
at least 60% in luminal diameter. The Quantitative angiography should 
show 60% diameter stenosis or a minimum luminal diameter less than 
1.7mm.The Doppler criteria to define ARAS includes peak systolic 
velocity >320 cm/s. The renal aortic ratio of 3.8 is for diagnosis of 
ARAS.
10
 
Renal artery disease (RAD) is defined as a stenosis of the main 
renal artery or its proximal branches. Atherosclerosis is the most 
common cause of renal artery stenosis, but may also be due to fibrous 
dysplasia of the renal artery. In children, most common cause of renal 
artery stenosis is due to fibromuscular dysplasia. 
 
 
14 
 
 
 
 
 
 
NON SELECTIVE RENAL ANGIOGRAM SHOWING 
ATHEROSCLEROTIC RENAL ARTERY STENOSIS 
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The anatomical definition to label renal artery stenosis is >50% 
occlusion but to be hemodynamically significant the stenosis should 
exceed by 70%. Hemodynamically significant lesions are the major 
concern as they may result in renovascular hypertension (RVHT) or 
ischemic nephropathy. 
RVHT is defined as systemic hypertension secondary to 
hemodynamically significant renal artery stenosis. In unilateral renal 
artery stenosis (RAS), affected kidney increased renin secretion and it is 
suppressed by the contra-lateral kidney. Angiotensin II constricts blood 
vessels and leads to hypertension, and enhances the aldosterone 
synthesis. Aldosterone causes sodium and fluid retention. With sodium 
retention, volume expansion, and hypertension, the contralateral kidney 
responds with diuresis leading to sodium and water excretion to restore 
plasma volume to normal. In bilateral RAS, both kidneys increase renin 
secretion. Impaired kidney function rapidly increases plasma volume 
and with plasma volume, renin secretion will ultimately decrease. 
Sympathetic nervous system, nitric oxide, and others are involved in the 
development of renovascular hypertension.
11 
 RVHT can be effectively treated with ACE inhibitors or ARBs, 
but may be complicated by an increased risk for adverse effects, 
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specifically an acute decline in GFR soon after beginning therapy. 
Ischemic nephropathy is defined as decreased GFR due to 
hemodynamically significant RAD. 
Etiology of Renal artery stenosis 
The etiology for renal artery stenosis is mainly contributed by 
atherosclerosis in >90% of the population and the rest by fibromuscular 
dysplasia .This is from western data. The scenario is entirely different in 
the Indian subcontinent up to 70% RAS is mostly caused by takayasu’s 
arteritis. The atherosclerotic process in renal arteries is long standing 
leading to parenchymal injury and renal impairment and hence 
revascularization may not be beneficial. There is a real challenge in 
identifying patients who will benefit from renal revascularization.
4
 
The ARAS involves the ostium, proximal one third and perirenal 
portion of aorta. The rate of progression of ARAS is not clearly evident 
from studies. In the 90s the data shows 51% progression at 5yrs after 
diagnosis an occlusion rate of 5% per year. The DRASTIC study 
showed 16% in the drug cohort progressed to ARAS at 1 year.
12 
In a 
study of 1189 patients undergoing cardiac cathetrization11% progressed 
and 0.3% showed total occlusion.
13
 
 
 
17 
Fibromuscular dysplasia is seen in younger age. It is most 
commonly seen in females. It can involve all the three layers of vessel. 
It shows a classic “string of beads” appearance on Digital subtraction 
angiography. It is heterogeneous in its presentation and long term 
studies not available on the rate of progression. It responds well to 
balloon angioplasty. The rate of restenosis is less. 
 
 
 
 
 
 
 
 
 
 
 
Etiology of renal artery stenosis and occlusion 
Disease        Prevalence 
        
 Atherosclerotic renal artery disease  -  85 – 90% 
 Fibromuscular disease    -  ~ 10% 
 Acute renal artery occlusion ( thrombosis,  
embolism , trauma)     -  < 2% 
 Aortic dissection with renal Artery involvement-   < 1% 
 Takayasu / Giant cell Arteries   -   < 1% 
 Mid – Aortic syndrome    -  Rare 
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The other causes are takayasu arthritis is relatively common in 
Indian subcontinent. It involves aorta and its major branches .the renal 
artery involvement in seen in 26% of the cases.
10
 
Vascular Injury to the kidney 
The renal circulation is unique. It is loaded with the function of 
filtering 140-150 liters of fluid daily. There is extensive glomerular 
capillary network. Even a slightest insult will present with predictors 
that will helpful to risk satisfy both renal as well as systemic disease.  
The insult to kidneys, not only threaten the viability of kidney, but 
in large compromise the fluid & electrolyte homeostasis.  
Hypertension, atherosclerosis, embolism, inflammation and 
hematological vascular diseases are the common causes. 
The renal endothelial injury easily present as increased urinary 
albumin excretion. It serves as a marker of athero vascular disease 
(AVD). 
Patho physiology 
The genesis of atherosclerosis usually progress from clinically 
silent vasculopathy to adverse Cardiovascular (CV) events. The non 
modifiable risk factors include age, sex, birth weight and genetic factors. 
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The modifiable risk factors include hypertension, smoking, diabetes, 
dyslipidemia and obesity. All factors result in endothelial dysfunction. 
The renal manifestations are HT and decreased GFR. The renin 
and sympathetic nervous system gets activated resulting in frequent 
flushing, nocturnal BP non dippers, and rapid BP swingers. Flash 
pulmonary edema is a common clinical manifestation of renal artery 
stenosis. RAS cases are more likely to suffer from CV events than 
ischemic nephropathy.  
Renal artery stenosis, Hypertension and cardiovascular risk 
The concept that many hypertensive populations do not have 
elevated blood pressure at the time of presentation and the CV risk 
should be taken into account of the global risk. The risk factors are 
additive and complement each other. The combination of ARAS, HT is 
a high risk category and its management includes aggressive 
management of risk factors and hypertension. The CV risk increases 
linearly from a blood pressure level as low as 115mm HG. There is a 
doubling of mortality for every 20mm Hg increase in systolic and every 
10mm hg increase in diastolic BP.
8
 
The cardiovascular mortality is on the decrease due to advances in 
the management particularly intervention is on the peak. Still ARAS is 
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silent killer of heart. It is an independent cardiovascular risk factor. It is 
turning out to be leading cause of death 16%year
.10 
The increased cardiovascular risk in ARAS is due to 
hypertension, decreased GFR and concomitant atherosclerosis in other 
CV beds. The mechanisms are due to RAAS and sympathetic activation. 
The RAAS system activation is a transient phenomenon and the blood 
pressure rise is sustained by alternative pathways such as inflammation, 
endothelial dysfunction and oxidatory pathways.
14
 The levels of renin 
starts to decline as the perfusion pressures decreases that corresponds to 
a trans lesion gradient 10-20%.however the lateralized plasma renin 
assays are helpful in suggesting a significant kidney disease. The 
captopril renin assays has lost its place as it does not give a visual 
estimation of RAS. The test is no longer recommended as ARAS 
hypertension is not renin dependent. 
Risk factors of RAS 
The concept of risk factor is that it should detect future event risks 
of the particular system in the body. The major risk factors for the 
atherosclerotic disease are listed below. 
 
 
 
21 
Conventional risk factors  other risk factors 
1. Hypertension                            1.  Obesity 
2. Diabetes      2.Familyhistory                                                                 
3. Male sex          3.Dyslipidemia   
4. Smoking 
5. Advancing age 
Risk factor for ischemic renal disease 
1. Hypertension: It can be cause as well as consequence. 35% of the 
patients with renal diseases have normal blood pressure. 
2. Renal insufficiency 
3.  Diabetes 
4.  Smoking 
The conventional risk factors are not useful in screening RAS. 
Screening RAS has been important as it helps in early intervention that 
helps ameliorate BP rise, prevent renal insufficiency and protect heart 
from cardio destabilization syndromes. These established risk factors for 
atherosclerotic diseases cannot be exactly extrapolated to renal artery 
disease.  
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There are emerging predictors of renal artery stenosis 
1. Homocysteine 
2. C –Reactive protein 
3. Fibrinogen 
4. Lipoprotein-A 
 The role for this emerging risk factor is helpful in detecting 
ARAS at an earlier stage .Modification of this risk factor with drugs like 
Statins may prevent progression of ARAS.
15
 
 Hypertension is known and well established risk factor. It 
damages the intimal layer and causes endothelial dysfunction. For every 
20/10 mmHg blood pressure increase there is doubling of mortality for 
ischemic heart disease and stroke. The mortality risk starts with the 
blood pressure of 115/75mmHG. CAD, Hyperlipidemia and 
Hypertension are the most important predictors of renal artery disease.
16 
 
ARAS has higher incidence of HT approximately 80% .Of the HT 
patients 60% approximately, are resistant HT. Bilateral renal disease 
presents with refractory HT. An interesting finding is that hypokalemia 
is associated with severe HT. Age greater or equal to 65 years, resistant 
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hypertension, type2 diabetes mellitus, multi vessel CAD are considered 
independent risk factors for ARAS.  
The Chinese study tried to create a logistical model including risk 
factors for patients undergoing CAG. The risk factor included age 
>65yrs, gfr <60ml/min/m
2
, multivessel CAD and resistant hypertension. 
The equation is“P/ (1−P) = exp (−2.618+1.112 [age≥65 years] + 
1.891 [resistant hypertension] + 0.453 [type 2 diabetes] + 0.587 [Ccr≤60 
ml/min] +2.254 (multivessel coronary disease)” 
This regression model has been used to screen ARAS with a 
sensitivity of 81.2%, specificity of 88.9%, and positive and negative 
predictive accuracies of 53.8% and 96.7%, respectively.
17 
 Early recognition is extremely important in detecting this deadly 
disease. It is a progressive and the rate of occlusion between 10-20%.the 
clinical clues as given by guidelines should be picked up and 
investigated further. When the clinical suspicion is high and the other 
noninvasive tests inconsistent invasive renal angiography has been 
recommended. It can also be apart of coronary angiography if patients 
are found at increased risk for RAS.
18 
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RAS and CAD 
The incidence of RAS in CAD is higher compared to normal 
coronaries .The incidence tends to be higher in multivessel disease 
particularly in triple vessel disease. The coronary anatomy has higher 
predictive role in identifying ARAS. The screening for RAS has been 
recommended in those who have greater than two vessel disease. The 
other risk factors that have even higher risk are elevated systolic BP, 
Diabetes, and reduced eGFR
.18
 The natural history for ARAS in 
asymptomatic cases are favorable, in fact intervention should be 
deferred. 
Clinical features: Clues to suspect RAS 
Clinical clues to renovascular disease include (1)onset of 
hypertension before age 30 (especially without a family history) or 
recent onset of significant hypertension after age 55; (2) an abdominal 
bruit, particularly if it continues into diastole and is lateralized; (3) 
accelerated or resistant hypertension;(4) recurrent (flash) pulmonary 
edema; (5)renal failure of uncertain etiology, especially with a normal 
urinary sediment; (6) coexisting diffuse atherosclerotic vascular disease, 
especially in heavy smokers; or (7) acute renal failure precipitated by 
antihypertensive therapy, particularly ACEIs or ARBs. 
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  Clinical clues to the diagnosis of  Atherosclerotic Renal Artery 
Stenosis :  
1. Hypertension onset before the age of 30y or severe hypertension 
after the age 55yrs ( class I . level of evidence (LOE) B) 
2. Resistant, malignant and accelerated hypertension (class I, LOE 
C) 
3.  New azotemia or the development of worsening renal function 
after treatment with an angiotensin  – converting enzyme inhibitor 
or angiotensin receptor blocker (class I, LOE B) 
4. When there is no cause for atrophic kidney or discrepancy in size 
between the two kidneys > 1.5 cm between kidneys ( class I , 
LOE B) 
5. Development of  sudden unexplained pulmonary edema (class I) 
6. Unexplained deterioration of kidney function, including patients 
starting renal replacement treatment ( Class II a, LOE B) 
7. The presence of 3VD or Multi vessel coronary artery disease or 
peripheral arterial disease (class II b, LOE B) 
8. The presence of Unexplained congestive heart failure or 
refractory angina  ( class II, LOE C).
1
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Investigations of RAS 
It should begin with non invasive modalities. The most common 
screening tool is doppler USG. The sensitivity is 70%. 
Doppler USG 
The Doppler is a valuable tool in assessing significant RAS. This 
is a initial screening tool in evaluation of suspected RAS. The pulse 
Doppler spectrum of renal parenchyma shows early peak systolic 
velocity and the end diastolic velocity. Resistive index difference is 
defined as a ratio of end diastolic velocity to peak systolic velocity. A 
value of > 0.05 indicates significant RAS of >70%. The other indices 
helpful in suspecting RAS are Peak systolic velocity between 200 -
320cm/s or Renal Aortic ratio >3.5-3.8. 
 Measurement of intra renal resistive index is more valuable in 
assessing parenchymal disease. A RI < 0.8 is a prerequisite for 
revascularization in renal artery stenosis. It is a prognostic tool in 
assessing recovery following RAS stenting.  
The contralateral kidney usually shows compensatory 
Hypertrophy. The absence of hypertrophy should arouse suspicion of 
bilateral disease. Hypertensive nephropathy and diabetic nephropathy 
are other causes since they result in parenchymal disease. 
10
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In 2001, Radermacher et al evaluated 5950 patients with 
hypertension for renal artery stenosis using color doppler 
ultrasonography to predict the outcome of therapy for RAS. Resistance 
index can be used to select appropriate patients for treatment. 
Among138 patients with >50% of the luminal diameter underwent renal 
angioplasty or surgery and the procedure was successful in 131 (95%) 
patients. In 35 patients who had resistance index if least 80 before 
revascularization, mean arterial pressure did not decrease by 10mm Hg 
or more after revascularization in 34(97%). In 96 patients (73%) with a 
resistance index of <80, mean arterial pressure reduced at least 10% in 
all expect 6 patients. Study concluded that resistance index value of at 
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least 80 reliably identify patients with renal artery stenosis in whom 
surgical intervention will not help improving BP, renal function or 
kidney survival.
20
 
 
CT Angiography 
CT angio has advantage of faster acquisition of images but the 
ionizing risk and nephrotoxicity is high. It delineates accurately smaller 
sized vessels. The sensitivity and specificity compared to renal 
angiography is 94% & 93% respectively.
21
It is a less invasive procedure. 
It has its own limitations; the presence of calcium obscures the luminal 
stenosis. Further it is not a physiological assessment of renal artery 
stenosis. 
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MR Angio 
This topographic imaging gives anatomic and physiologic 
assessment of kidneys accurately. It validates glomerular filtration as 
well as renal blood flow. The cross sectional area of renal arteries is well 
assessed. A new emerging MR technique called BLOOD OXYGEN 
LEVEL DEPENDENT (BOLD) helps in greater functional assessment 
of ARAS. It assess the renal levels of deoxyhemoglobin thereby 
functional status of kidneys after the stenosis .The image below shows 
bilateral renal artery stenosis and asymmetric kidneys.
10
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Echocardiography 
The echo is useful in assessing cardio vascular and renal risk.The 
ASE has recommendations that diastolic assessment is an important 
paramater in assessment of heart failure with preserved ejection 
fraction.Relative wall thickness is 2 x posterior wall thickness divided 
by end diastolic left ventricle dimension. It gives whether it is concentric 
or eccentric Left ventricular hypertrophy. The Left ventricular mass 
divided to body surface area has been more accurate in assessing organ 
damage.the Left atria volume has grater prognostic implications. 
Renal Angiography 
Anatomical Landmark L1 –L2 Vertebrae  
Accessory renal artery is seen in 25% of the patients .I t usually 
supplies lower pole of kidney. 
Renal angiography is the gold standard technique for imaging 
renal arteries. It is mostly required in ambiguous non-invasive imaging 
diagnosis of RAS or as apart of cardiac catheterization. 
Renal Arteries originates from the Abdominal Aorta laterally .The 
access to the renal artery is done through, trans-femoral, trans-radial, 
trans-brachial routes. The take off arteries decides the route. Mostly 
after completion of cardiac catheterization, renal arteries are accessed  
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RIGHT RENAL ANGIOGRAM SHOWING  
NORMAL RENAL ARTERY 
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commonly through the trans-femoral route. Downward angulation 
of renal arteries necessitates trans–renal or trans–brachial routes. 
The renal angiography is initially done non-selectively by 
injecting contrast in a multi hold catheter like pig tail .After accessing 
renal arteries, through catheters like judkins right, internal mammary 
and hockey stick catheters selective renal angiography is done. 
          As the origin of the renal arteries is variable, the views should be 
placed such that the origin of renal arteries displayed in face. Usually 
AP view with slight LAO/RAO tilt is used. Caution should be exercised. 
No touch technique should be used, such that the atheroma in the aorta 
is not dislodged in to the renal artery during catheter manipulation. 
 In indeterminate renal angiography, the hemodynamic 
significance of the lesion is accessed by Trans stenotic gradient.  It is 
achieved by using .014 inch FFR wire. The presence of systolic gradient 
more than 20mm Hg or a mean gradient of 10mm Hg is considered 
significant. The role of IVUS is very helpful, when per-cutaneous renal 
vascularization is planned.  The IVUS gives greater image resolution of 
all renal artery sizes. 
 Once the severity of renal artery is accessed, the stenting can be 
performed according to AHA guidelines. The rate of complication of 
using catheter based angiography is very low. 
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        The complications of renal angiography are 
1. Athero-embolization 
2. Contrast induced nephropathy 
3. Access site complication/damage 
4. Bleeding 
5. Contrast allergy 
Procedural Angiographic complications  
  Dissection  
  Branch vessel occlusion  
  Angiographic distal embolization  
  Wire perforation   
  Vessel rupture  
  Pseudo aneurysm  
Pre-procedure preparation  
1. Hydration with intravenous fluids before injection of contrast 
2. Tablet N-Acetyl cysteine 600mg BD before and after the 
procedure 
3. Iso–osmolar / non-ionic contrast 
4. Maximal information obtained through non-invasive imaging 
studies 
5. IV sodium bicarbonate may be considered 
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It is highly sensitive and specific test, but it is invasive. To reduce 
the radiation exposure, digital subtraction angiography should be 
considered. 
Alternative angiographic techniques like carbon dioxide/ 
gadolinium contrast agents can be used. 
 The catheter size should be 5F or 6F of renal angiography.
22 23
 
Percutaneous renal intervention  
 After the RAS is measured and quantified by radial angiography, 
the angioplasty balloon is advanced over the guide wire and positioned 
at the lesion. The balloon dilation should be at the ratio of 1:1.While 
removing the balloon after dilation the catheter should be pushed for 
correct deployment of stent. Distal protection devices can be used to 
protect the cholesterol embolization. 
“SZABO technique is another safe and reproducible technique to 
exactly deploy stents at the aortic renal artery junction. This technique 
was initially used in coronary artery ostial lesions and can also be used 
in guiding and deploying renal stents into position at the aortic renal 
junction. Here, for the exact deployment, two 0.014 inch wire (with the 
second wire inserted through the last cell of a stent) are used for stent 
deployment. This stent tail wire or anchor technique facilitates precise 
aorta-ostial stent deployment in case of atherosclerotic RAS. It also 
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helps to eliminate errors of improper stent positioning at this aorto renal 
junction, and may possibly minimize patient exposure to ionizing 
radiation and contrast dye”. 
Screening ARAS: should renal angiogram (RAG) be a part of 
Coronary angiogram (CAG) 
The AHA science advisory recommends screening renal 
angiography as part of cardiac catheterization on patients at high risk for 
ARAS who are potential candidates for renal intervention/surgical 
revascularization.
24
 Is routine screening for ARAS worthful, useful? 
Although the procedure is safe and convenient whether it has a high 
diagnostic yield? Even if it yields does it leads to a successful outcome?. 
The committee advises against routine screening for RAS during cardiac 
catheterization except in patients at high risk for RAS.  
There are dangers of early intervention, the natural history of 
disease unclear. The editorial is against routine screening that may lead 
to over diagnosis and over treatment. The screening for RAS does not 
lead to increased survival. 
Any screening program’s purpose is to serve by improving 
survival. The patients on cardiac disease are already on maximal 
treatment. The additional diagnosis of ARAS had great enthusiasm 
among interventional cardiologists. They literally jumped in doing renal 
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intervention .But till today all the trials has failed to show renal stenting 
s’ superiority over medical management. 
But there are patients to be identified who would really benefit 
from revascularization. It is still a difficult question that is still 
unanswered. 
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Flow chart of primary renal assessment 
10
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Management of RAS  
All renal artery stenosis need not be stented and should not be. So 
far all the randomized control trials did not favor routine stenting .it is a 
controversy continuing with lot of hot debates? Interventional 
cardiologists show a trend towards percutaneous renal artery stenting. 
The arguments put forward favoring intervention is that the major trials 
are seriously flawed. The inclusion of RAS included lesions greater than 
50% most clinicians recommend lesions >70% are significant; stenting 
should be preferred over balloon angioplasty, lot of crossover between 
groups. The current indications of stenting ARAS should follow AHA 
guidelines till large RCTs modify the current scenario. 
ASTRAL 
The Angioplasty and Stenting for Renal Artery Lesions 
(ASTRAL)  
This trial was designed on the background that if renal artery 
patency is maintained then it should derive clinical benefit. But contrary 
to the expectations it did not show improvement in renal function which 
is a primary endpoint. This 34 yr median follow up study showed higher 
complication rates included death and limb loss. It did not find upper 
hand over medical management.  
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Authors’ conclusions 
“We found substantial risks but no evidence of a worthwhile 
clinical benefit from revascularization in patients with atherosclerotic 
renovascular disease”. 25 
Star   
“Stent Placement in Patients with Atherosclerotic Renal Artery 
Stenosis and Impaired Renal Function” 
The aggressive medical management of RAS offers greater 
benefit compared to stenting. The exact mechanism how it acts on the 
intra renal compartment is not addressed. This study compared the two 
strategies. They concluded that renal artery stenting did not score over 
medical therapy. “Stent placement with medical treatment had no 
clear effect on progression of impaired renal function but led to a small 
number of significant procedure-related complications”.26 
Drastic trial 
The experiments conducted by gold blatt showed renal 
constriction resulted in high blood pressure. Initially surgical 
revascularization was the only treatment option available for RAS. But 
the great enthusiasm that was shown towards renal angioplasties in 
treating RAS formed the background of the study. In the treatment of 
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patients with hypertension and renal-artery stenosis, angioplasty has 
little advantage over antihypertensive-drug therapy.” The limitations in 
the study are 
 The sample size was insufficient 
 Balloon angioplasty without stenting was Used 
 Renal artery stenosis was defined as greater than 50% stenosis 
 Twenty-two of the 50 patients randomized to medical therapy 
crossed over to the angioplasty group 
There was great success in fibromuscular dysplasia.  But majority 
of RAS is due to atherosclerosis. The primary endpoint is control of BP. 
The study results shows no greater reduction of BP compared to medical 
management.
12
 
Coral 
 “A Randomized Multicenter Clinical Trial of Renal Artery 
Stenting in Preventing Cardiovascular and Renal Events”: Results of the 
CORAL Study.   It concluded “Renal artery stenting did not confer a 
benefit to the prevention of clinical events when added to 
comprehensive, multi-factorial medical therapy in people with 
atherosclerotic renal artery stenosis and hypertension or chronic kidney 
disease”.  
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CORAL confirms the current ACC/AHA guidelines. “Medical 
therapy should be the initial therapy for renal artery stenosis and 
difficult to control blood pressure. In patients in whom blood pressure 
cannot be controlled on 3 medications, one of which is a diuretic or for 
patients who cannot tolerate medications and who have severe renal 
stenosis, renal artery stenting remains a reasonable option”.27 
In 2000, Long term effects of balloon angioplasty on hypertension 
in patients with atherosclerotic renal artery stenosis were studied in 106 
patients by Jaarsveld and his team. At three months, the blood pressures 
were similar in the two groups. Patients in the angioplasty group were 
taking 2.1 & 1.3 defined daily doses of medication and those in the 
drug- therapy group were taking 3.2 & 1.5 daily doses. 22 patients in the 
drug treatment group underwent angioplasty after 3 months because of 
persistent blood pressure despite of taking more than 3 drugs. At 12 
months, there was no difference between both drug treatment and 
balloon angioplasty group in SBP, DBP, daily drug dose or renal 
function. 
Dorres G et al in 2002 conducted multicenter trial in1058 patients 
with renal artery stenosis. Patients underwent revascularization 
procedure with palmaz stent and followed up for four years. At 4 years, 
SBP and DBP had significantly decreased with concomitant decrease in 
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number of drugs used. Cumulative probability of survival was 74% at 4 
years. Survival was good for patients with normal (85% +/- 3%) 
baseline renal function, fair (78% +/- 5%) with mildly impaired renal 
function, and poor (49% +/- 5%) with severely impaired renal function 
(baseline creatinine > or =2.0 mg/dl). The combination of impaired renal 
function and bilateral disease adversely effected survival.  Survival was 
adversely effected by renal dysfunction despite adequate 
revascularization.
28
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MATERIALS AND METHODS 
This study was done with the aim of screening renal artery 
stenosis in patients with hypertension who are admitted in our hospital 
for coronary angiography and predicting risk factors association with 
ARAS. 
Place of study Department of cardiology, 
Government Rajaji hospital and 
Madurai medical college, Madurai. 
Type of study Observational analytical study 
Institutional ethics committee Approval obtained 
Collaborating departments Department of Biochemistry 
Period of Study 6 months 
Financial Support Nil 
Conflict of Interest Nil 
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STUDY POPULATION: 
This study was conducted among 75 Hypertensive Patients 
admitted for coronary angiogram / intervention   in cardiology ward   at 
the Government Rajaji Hospital, Madurai, after getting the institutional 
ethics committee approval. Informed and written consent was obtained 
from each patient before being included in the study. 
Inclusion Criteria 
Patients admitted with a history of Hypertension and planned 
CAG / intervention for suspected/diagnosed CAD in cardiology ward. 
Exclusion criteria 
1. Doesn't opt for inclusion in the study 
2. Pregnancy 
3. Age less than 30yrs 
4. Chronic renal insufficiency GFR <60ml/min/m2 
5.  Patients with EF less < 30% 
6.  History of allergy 
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Data Collection and Methods 
CLINICAL analysis includes presence of signs of hypertension, 
CAD and RAD. etc. LABORATORY PROFILE study includes blood 
counts, urea, creatinine, lipid profile, ECG, echocardiogram for all 
patients, treatment details to be collected including drugs for HT, Heart 
and kidney. CAG and Renal angiogram 
OUTCOME includes identify patients with high risk clinical 
predictors and prevalence of significant RAS thereby recommend 
Screening in that subgroup and planned revascularization.  
 
PROCEDURE: 
The patients undergoing cardiac coronary angiography, renal 
angiography is planned after completion of the CAG. Immediately after 
injecting contrast in right coronary artery the catheter  (Judkins right) is 
slowly brought down in the aorta to the anatomical land mark of renal 
arteries(L1_L2 vertebrae).The renal arteries are selectively cannulated 
and renal angiogram is completed. In difficult cases non-selective renal 
angiogram is done using pig tail catheter. 
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Statistical Analysis: 
The information collected regarding all the selected cases were 
recorded in a master chart. Data analysis was done with the help of 
computer by using SPSS software and Sigma Stat 3.5 version (2012). 
Using this software, range, frequencies, percentage, mean, standard 
deviation and ‘p’ value were calculated through One way ANOVA, Chi 
square,  Pearson and Spearman Correlation test and  P value of < 0.05 
was taken as significant. 
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SELECTIVE LEFT RENAL ANGIOGRAM USING  
JUDKINS RIGHT CATHETOR SHOWING 
 RENAL ARTERY STENOSIS IN THE  
PROXIMAL ONE THIRD 
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RENAL ANGIOGRAM AFTER 
RENAL ARTERY STENTING 
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RESULTS 
 
Table – 1 
Age Distribution 
Age in Years Total no. of cases RAS 
<  40 years 4 0 
41 – 55 22 1 
56 – 70 43 11 
>  70 years 6 3 
Total 75 15 
 
  Mean Age  - 59.5 years 
  Range  - 34-80 years 
  < 55 years  - 1 / 26 
  > 55 years  - 14 / 49 
   ‘p’ value  - 0.033 Significant 
In this study, Out of 75 cases, 26 cases in less than 55 years age group 
and 49 cases in more than 55 years age group. 
 When compared with age group, most of the RAS cases (93%) is 
in   > 55 years age group.  It is also statistically significant i.e. ‘p’ value 
is 0.033. 
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Table – 2 
Sex Distribution 
Sex Total no. of cases RAS 
Male 49 5 
Female 26 10 
 
   Male  - 5 / 49  
   Female - 10 / 26  
   ‘p’ value - 0.043  Significant 
 Male: Female ratio - 1.8 
 In this study, males are participated more when compared with 
females (65% / 35%) 
 When compared with RAS,  out of 26 females, 10 cases in RAS 
but only 5 cases (RAS) in males out of 49.  
 It is also statistically significant ‘p’ = 0.043 
    
 
 
 
 
 
 
53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49
5
26
10
0
5
10
15
20
25
30
35
40
45
50
Male Female
SEX DISTRIBUTION
Total no.of cases RAS
 
 
 
54 
Table – 3 
Prevalence of Renal artery stenosis (N = 75 cases) 
 No. of cases Percentage 
Unilateral 13 17.33 % 
Bilateral 2 2.66 % 
Total 15 20 % 
 
 
Table – 4 
Smoking, Diabetes and Hyperlipidemia 
Parameters Total no. of cases RAS ‘p’ value 
Smoking 20 4 0.749 
Not Significant 
Diabetes 19 6 0.400 
Not Significant 
Hyperlipidemia 13 5 0.289 
Not significant 
 
 Smoking, Diabetes and Hyperlipidemia are not significantly 
affecting RAS factor. 
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Table – 5 
Hypertension Stages 
Stages Total no. of cases RAS 
Stage  I 39 3 
Stage II 36 12 
Total 75 15 
 
   Stage I  - 3 / 39  
   Stage II  - 12 / 36 
   ‘P’ value  - 0.047   Significant 
Association of RAS and Resistant HT: 
There was (39/75) cases of stage I HT and the presence of RAS 
(3/39) were not significantly increased. There was (36/75) cases of stage 
II HT and the presence of RAS (12/36) were significantly increased. 
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Table – 6 
Resistant HT 
 Total no. of cases RAS 
Resistant 5 4 
Non Resistant 70 11 
Total 75 15 
 
   Resistant  - 4 / 5 
   Non Resistant - 11 / 70 
   ‘p’ value  - 0.039  Significant 
Association of RAS and Resistant HT: 
There was (5/75) cases of resistant HT and the presence of RAS 
(4/5) was significantly increased. The resistant HT is a powerful 
predictor of RAS in our study. The resistant HT cases had a dramatic 
course of adverse CV events.   
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Table – 7 
Duration of HT 
Duration Total no. of cases RAS 
0 – 6 months 15 1 
7 months -  2 years 28 2 
2 years -  5 years 20 5 
  5 years – 10 years 11 5 
>  10 years 1 1 
Total 75 5 
 
  ‘p’ value - 0.027   Significant 
Association of RAS and duration of HT: 
The duration of hypertension has linear correlation. As duration 
of hypertension increases above 5yrs there is increased prevalence of 
RAS. There were (11/75) cases of HT with duration >5yrs and the 
presence of RAS (5/11) was significantly increased. There were (1/75) 
cases of HT with duration>10 yrs, and the presence of RAS (1/1) was 
significantly increased. 
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Table – 8 
CAD   vs   RAS 
 Total no. of cases RAS 
CSA 11 2 
UA / NSTEMI 22 5 
STEMI 42 9 
 
  CSA  - 2 / 11 
  UA/NSTEMI - 5 / 22 
  STEMI - 9 / 42 
 ‘p’ value  - 0.952  Not significant 
Association of RAS and clinical presentation of Coronary artery 
disease:  
Most of the cases presented as STEMI (42/75). There was no 
significant association between clinical presentation and presence of 
RAS. There was (22/75) cases of unstable angina and the presence of 
RAS were not significantly increased. There was (2/11) cases of stable 
angina and the presence of RAS were not significantly increased     
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Table – 9 
Heart Failure / pulmonary edema vs   RAS 
HF / PE   Total no. of cases RAS 
Yes 15 10 
No 60 5 
Total 75 15 
 
   HE/PE Yes - 10 / 15 
                 No - 5 / 60 
   ‘p’ value  - < 0.001  Significant 
Association of RAS and clinical presentation of Coronary artery 
disease as heart failure/pulmonary edema: 
 The cases presented as heart failure are (15/75). There was 
significant association between clinical presentation as heart failure and 
presence of RAS.  
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Table – 10 
CAD/Angio vs   RAS 
CAD/Angio   Total no. of cases RAS 
SVD 34 3 
2VD 18 3 
3VD 17 9 
LMCA 2 0 
Normal 4 0 
Total 75 15 
 
   3VD - 9 / 17  
  Others - 6 / 58 
  ‘p’ value - 0.009   significant 
Association of RAS and angiographic presentation of Coronary 
artery disease: 
Most of the cases presented as single vessel disease (34/75). 
There was no significant association between SVD presentation and 
presence of RAS (3/34). There was (18/75) cases of 2Vd and the 
presence of RAS (3/18) were not significantly increased. There was 
(17/75) cases of triple vessel disease and the presence of RAS (9/17) 
were statistically significantly increased.     
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DISCUSSION 
Prevalence and predictors of RAS 
RAS is a major comorbid and independent risk factor for 
cardiovascular disease. The western data shows a prevalence of 13.5-
18% in patients undergoing Coronary angiography for suspected 
coronary artery disease. Less data is available from the Indian 
subcontinent.  
The prevalence of RAS in our study conducted over 75 patients is 
20% (15/75). The mean age is 59.5 yrs. Most of the patients are males. 
STEMI is the common clinical presentation. The conventional risk 
factors like smoking, diabetes and dyslipidemia did not find significant 
association. The stage II Hypertension predicted RAS. The coexistence 
of resistant hypertension and heart failure increases the predictability of 
RAS in the study group.  
The prevalence of RAS in Japanese population undergoing CAG 
is 7%.In the sub group analysis the prevalence of RAS was 5%, 10%, 
9% and 19% for 0, SVD, 2VD, 3VD respectively. The prevalence in 
hypertension population was 13% and 2% in non hypertensives.
29
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In the sub group analysis of our study, the prevalence of RAS was 
4%, 4%, and 12% for SVD, 2VD, 3VD respectively. We therefore find 
that screening for RAS should be a part in triple vessel disease and 
Hypertensive population.  
RAS has deleterious effect on heart and portends poor prognosis. 
It is high time that cardiologist should perceive atherosclerosis as a 
global risk involving multiple beds. The aggressive nature of 
interventional cardiologist is to be justified. Atherosclerotic RAS is the 
most common cause for secondary hypertension.  
The Indian study conducted over 469 patients underwent coronary 
angiogram were screened for RAS by conventional renal angiography. 
The prevalence of RAS was 66/469 and 36 had significant ARAS. Of 
the 36 RAS patients 33 had significant CAD and had no CAD patients.
30
      
There is always a debate on which patients renal angio should be used 
for screening RAS. The renal angiography has been recommended on 
patients with atherosclerosis on coronary and peripheral beds. 
It is also recommended on patients who undergo 
coronary/peripheral angiogram to screen for ARAS if they have severe 
atherosclerosis, resistant hypertension, flash pulmonary edema and triple 
vessel disease.  
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Another Indian study by PC Rath et al concluded that the 
incidence of RAS was statistically not significant but showed increased 
incidence among multiple risk factors and severe coronary artery 
disease. This study showed hypertension, diabetes smoking, females, 
elderly age and triple vessel disease as significant risk factors. The 
prevalence for significant RAS over 1000 patients was 2.5%.
31
  
The patients underwent selective renal angiography. It was 
performed in all the patients after CAG. 84.9% of the patients had 
significant coronary artery disease. Of the total patient cohort, 103 
(10.3%) patients had renal artery disease. But significant RAS over 1000 
patients was 2.5% only. 
This study made us to screen RAS in a subset of patients such that 
unnecessary renal angio could be avoided in a vast majority of patients. 
Though renal artery stenosis can be present in non hypertensives and 
normal coronary patients the number is too low. Hence we excluded this 
population from our study.  We have also excluded PAD in our study as 
to reduce access site complications.  
Our study found age >55yrs, female sex, duration of HT, 3VD, 
and resistant HT as predictors of RAS. 
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Though renal artery stenosis is not recognized at its first 
presentation, it is subsequently recognized at follow ups. Renal artery 
stenosis is increasingly recognized to be an independent predictor of 
survival in coronary artery disease. The prevalence compared to western 
data is relatively low. 
 Therefore long term follow up of patients with CAD is needed. 
Our study is only a cross sectional observational study. Since routine 
renal angiography is not warranted as screening purpose, we propose 
screening as part of CAG in selected subset like, 3VD, resistant HT 
heart failure/pulmonary edema 
Rimoldi SF et al, in 2010, retrospectively studied 1403 patients 
who underwent drive-by renal arteriography. The hypertensive 
population is the subset. It was conducted to determine the prevalence 
and predictors in unselected hypertensives. The prevalence of significant 
RAS was 8%. Independent predictors were coronary (OR 5.3%), 
peripheral (OR 3.3), and cerebral artery (OR 2.8) impaired renal 
function (OR 2.9). It was concluded that unselected patients undergoing 
coronary angiography was a low.
32
 
In our study we selected a Hypertensive population since the 
prevalence is very low in unselected patients. We excluded normal 
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coronary patients from screening. 
In 2001, Shurrab and colleagues have reviewed 249 patients 
undergoing angiography over the period of 18 months to identify the 
patients having the greatest likelihood of atherosclerotic renovascular 
disease.  166 (66.7%) patients had no evidence of ARVD, while only 83 
(33.3%) patients showed some degree of ARVD, 29 (35%) of which had 
bilateral renal artery disease. There was no significant difference 
between the ARVD group and the non-ARVD group for mean age (69.0 
years vs 63.3 years), male to female ratio, history of smoking (68.7% vs 
55.4%), severe hypertension (10.8% vs 9.0%), hypercholesterolemia 
(61.4% vs 47.0%), diabetes mellitus (28.6% vs 25.3%) or angiotensin 
converting enzyme inhibitor-related renal dysfunction (9.6% vs 6.1%). 
The other risk factors diabetes, smoking and dyslipidemia has no 
significant association with RAS.
33
 
Conlon PL et al investigated the effect of the severity of RAS on 
all-cause mortality with total of 3987 patients undergoing abdominal 
aortography immediately after coronary angiography. Significant RAS 
was found to be present in 4.8% of patients was bilateral in 0.8%. Four 
year unadjusted survival for patients with and without significant RAS 
was 57% and 89% respectively. Presence of RAS, increased age, the 
severity of coronary artery disease, and presence of comorbid disease, 
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reduced ejection fraction, symptoms of congestive cardiac failure, and 
the mode of treatment of coronary artery disease were the factors 
independently associated with decreased survival. Four-year adjusted 
survival for patients with 50%, 75%, and 95% stenosis was 70%, 68%, 
and 48%, respectively.
34
 
Harding MB and his colleague prospectively studied the 
prevalence and associated risk factors in patients undergoing routine 
cardiac catheterization. Out of 1302 patients undergoing abdominal 
aortogram, 30% of them were found to have renal artery disease and 
significant renal stenosis was found identified in 18.8 in 15% of the 
population.  Significant unilateral disease was present in 1%, and 
bilateral disease was present in 4%.
35
 
Multivariable predictors included age, severity of coronary artery 
disease, congestive heart failure, female gender, and peripheral vascular 
disease. Hypertension was not an associated variable. 
In 2005, Mauricio G. Cohen et al conducted a study in 843 
patients who underwent abdominal aortography during cardiac 
catheterization. The aim of the study is to formulate a score which 
would be able to identify high risk patients. The risk factors included in 
the predictive score are hypertension, Sex, PAD, 3VD, serum creatinine, 
number of CV drugs and past CABG.
36
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The low risk score is <5 and it correlated with a probability of 
significant RAS of 0.6 %. The high risk is score of >18 correlated with a 
probability of 62.1%. 
We did not formulate a predictive score in our study as there is 
only a small number of study populations. 
The luminal diameter of significant renal artery stenosis was 
>50% in our study. The relatively high prevalence in our population 
may be because of less stringent criteria. Resistant HT, duration of HT 
correlated significantly with RAS. The clinical presentation of CAD has 
no significance.  
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SUMMARY 
Prevalence of RAS in patients undergoing cardiac 
catheterization  
Study No. HT CAD RAS% 
Masoomi et al 122 122 95 23% 
Rimoldi et al 1403 1403 558 8% 
Robbins et al 110 110 69% 20% 
Yamashitaq et al 289 138 220 7% 
(16%)  HT 
Harding et al 1235 49% 66% 15% 
Rath et al 
I sathyamurthy et al 
Range 15%-23% 
Indian study 
1000 
469 
522 
287 
849 
360 
10.3%/2.5% 
14%(66) 
Our study 75 75 71 15(20%) 
 
The predictors in our study are 1) age >55yrs, 2)female sex, 3) 
stage II HT,5) Resistant HT and heart failure 5) 3VD, 6) 
duration of HT >5yrs are found statistically significant. 
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LIMITATIONS OF THE STUDY 
 
The study population was small and it is a single centre cross 
sectional observational study. 
Functional assessment of renal artery stenosis was not done. 
IVUS and FFR are not in our investigation strategy. 
There is a strong correlation of renal artery stenosis and 
peripheral artery disease but peripheral angio was not part of our study. 
Screening for ARAS in normal coronaries was done but it did not 
yield significantly. 
Overestimation of lesion severity was done because it is only a 
luminogram and orthogonal assessment is not done.  
Invasive renal angiography is recommended when clinical 
suspicion is high and noninvasive testing is inconclusive or inconsistent 
with the clinical evidence (Hirsch et al., 2006). Routine non invasive 
screening tests were not our investigation protocol. 
Only Hypertensive patients with suspected CAD were included in 
our study the chances for missing RAS lesions in non hypertensive CAD 
patients is a major limitation of our study. Hypertension is both a risk 
factor and consequence of RAS.  The causative role was not established. 
There is selection bias in our study. 
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CONCLUSION 
 
Renal Angiogram is the gold standard investigation of renal artery 
stenosis. The guidelines did not recommend routine use of renal angio 
for screening purpose. But there are high risk predictors which has been 
the importance of our study to identify patients who will be screened for 
RAS while doing coronary angiogram for suspected CAD.  
Because of oculostenotic reflex of interventional cardiologists 
there is an overestimation of lesion severity by visual estimation during 
renal angiography. There is an intention towards stenting of lesions. 
Large randomized control trials till now did not favor stenting of all 
lesions. But there are cases that would benefit stenting are cardiac 
destabilization syndromes, resistant hypertension and chronic renal 
insufficiency. There is no robust evidence to support this situation too. 
Presence of renal artery stenosis is an independent predictor of 
survival in associated CAD patients. It is an adverse prognostic indicator 
of atherosclerosis. 
In our study the absolute number of renal artery stenosis was 
found significant. Renal angiography is recommended to this subset of 
patient with severe CAD as part of screening strategy. The procedure is 
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found to be safe with no major complications. It can be done with 
limited fluoroscopy time. The amount of contrast is also very less. 
Routine practice of screening RAS and intervention is not cost 
effective if there is no immediate hazard or risk of progression of 
ARAS.  
The stent outcome is determined by trans-stenotic gradient. If the 
systolic gradient is greater than 21 mmHg it predicts control of blood 
pressure after stenting with unilateral RAS. The diameter stenosis 50% 
by angiography and renal fractional flow reserve do not predict 
outcomes after renal artery stenting.
10
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RECOMMENDATION 
 
 Routine screening of  Renal Artery stenosis is not recommended 
 The prevalence is significantly higher if hypertensive population 
with CAD is screened for ARAS 
 Female sex, elderly age, severe HT, triple vessel disease are 
significant association with ARAS 
 The presence of renal artery stenosis is a bad prognostic sign 
 Intense medical management should be the prime treatment 
strategy. 
 The role of renal artery stenting is still unresolved 
It is recommended to screen for ARAS in hypertensive patients with 
multiple risk factors and multivessel disease. 
It is necessary to detect ARAS to prevent ischemic nephropathy a 
reversible cause of chronic renal failure at an early stage.  
There is incomplete evidence to support revascularization in multi-
drug-resistant renovascular hypertension, advanced CKD (stages 4–5), 
or steadily deteriorating renal function, which is also true for the vast 
majority of ARAS patients who present with asymptomatic chronic 
kidney disease or hypertension and severe RAS. 
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PRESENTATION:               Chest pain:                                                           Pedal  edema: 
                                            Dyspnoea:                                                            Abd distension: 
                                            Syncope:                                                               Oliguria: 
                                            Palpitation:                                                          Fatigue: 
                                            Other: 
PAST  ILLNESS:               HT :  onset:  controlled:             
 Diabetes                                                         
                                             CAD: 
 PAD:                                    CVA: 
Medical History :  No of drugs for HT:  ACE/ARB:                            Compliance: 
PERSONAL HISTORY:     Smoking: 
CLINICAL FEATURES:     GE – 
                                          BP:                                                    PULSE: 
                                          CVS: 
                                          RS: 
                                          ABD:                                                CNS: 
Clinical Diagnosis:    CAD: 
          HT: 
          Accelerated /Resistant/Malignant:      
          Heart failure/ Pulmonary edema: 
 
 
 
PROFORMA 
 
NAME:                                            AGE/SEX:                              HT:                        WT:                    
BMI: 
 
CD NO.                                            IP/OP no.                                                            CCL NO.  
 
 
D.O.A:                                            D.O.D:                                                                   D.O.E: 
 
 
87 
 
Investigations:                Hb:                   TC:                         DC: P     L      E     M   
             Urine albumin: 
                                          RBS:                  Bl Urea:                Sr. Creatinine:  
GFR: 
Lipid profile: 
 
ECG:               Rate:                             Rhythm:                       P wave:                            PR int: 
                       QRSD:                          QRS axis:                       ST:                                    T : 
         LVH: 
ECHO data: 
                        LVID d:                    LVID s:                RWMA: AW/IW                              LVEF: 
                        IVS d:                       IVSs                     PW:                        RWT:                 LV mass:                         
 
USG/Doppler  Abdomen: 
 
Coronary Angiogram:    
1)SVD/  DVD/  TVD/ Left Main 
 
Renal  Angiogram :  
1) unilateral/Bilateral  
2) % stenosis: 
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1 302458 58 M       yes       2y 24   yes     yes             
2 302521 41 M yes       yes     6m 6     yes     yes           
3 302578 65 M       yes       3y 36   yes     Yes             
4 303452 52 F   yes yes   yes     6y 72   yes       yes           
5 303774 37 M       yes     yes 4m 4 yes               Yes     
6 303983 64 F         yes     5y 60   yes   yes     yes     yes   
7 304115 57 M yes     yes       1y 12     yes   yes             
8 304522 63 F         yes yes   10y 120     yes   yes             
9 304658 68 M   yes yes   yes     5y 60     yes yes yes     yes       
10 304856 55 F       yes     yes 2y 24     yes     yes           
11 304966 69 M yes yes yes   yes     8y 96     yes   yes             
12 304987 73 M yes       yes     10y 120     yes       yes     yes   
13 305554 62 M       yes       2y 24   yes     yes             
14 305587 38 F       yes       3y 36     yes     yes           
15 305630 60 M yes     yes       1y 12     yes   yes             
16 305755 58 M         yes     5y 60     yes     yes           
17 305861 67 F   yes yes yes       7y 84     yes   yes             
18 305910 57 M yes       yes     4m 4     yes yes   yes           
19 305934 51 F       yes       2y 24   yes         yes         
20 306005 72 M         yes     5y 60 yes         yes           
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21 306114 69 F         yes     10y 120     yes   yes         yes   
22 306184 55 M yes       yes     2y 24   yes     yes             
23 306235 62 F   yes yes yes       5y 60             yes         
24 306278 68 M yes     yes   yes   12y 144 yes   yes yes   yes       yes   
25 306450 57 M         yes     6m 6     yes           yes     
26 306564 40 F       yes       4m 4     yes       yes         
27 306700 63 M yes     yes       5m 5     yes   yes             
28 306787 58 F         yes     1y 12     yes       yes         
29 306865 80 M         yes     4y 48     yes   yes             
30 306921 68 M   yes yes   yes     8y 96   yes       yes       yes   
31 306954 57 M       yes       2y 24   yes     yes             
32 306888 49 M yes       yes     1y 12     yes yes         yes     
33 307024 66 F       yes       2y 24     yes   yes             
34 307058 46 M         yes     1y 12     yes       yes         
35 307070 67 M       yes       2y 24   yes     yes             
36 307104 72 F   yes yes   yes yes yes 4y 48     yes yes yes         yes yes 
37 307245 66 M         yes     3y 36     yes     yes       yes   
38 307268 43 F       yes       1y 12 yes           yes         
39 307312 58 F   yes yes   yes     2y 24     yes   yes             
40 307354 68 M yes     yes       6y 72     yes           yes     
41 307458 47 F       yes       1y 12   yes   yes     yes         
42 307493 72 M         yes yes   4y 48 yes           yes         
43 307512 57 M         yes     1y 12 yes   yes   yes             
44 307654 54 M       yes       3m 3     yes     Yes           
45 307688 70 F   yes yes yes       7y 84     yes yes     yes     yes yes 
46 307701 65 M         yes     5y 60   yes     yes             
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47 307763 45 M yes     yes       1y 12     yes     yes           
48 307823 55 M       yes       3m 3   yes     yes             
49 307885 66 F         yes     6m 6 yes       yes     yes       
50 307915 71 M         yes     4m 4   yes     yes             
51 307969 55 M       yes       1y 12     yes   yes             
52 308007 57 F   yes yes yes       6y 72     yes   yes             
53 308045 67 M yes       yes     3y 36     yes       yes         
54 308086 48 F       yes       6m 6   yes       yes           
55 308146 58 M yes yes yes yes       5y 60         yes             
56 308176 62 F   yes yes   yes     4y 48 yes     yes     yes     yes   
57 308190 59 F       yes       4y 48 yes       yes             
58 308212 70 M yes yes     yes     6y 72     yes       yes     yes   
59 308263 66 M       yes       4m 4     yes yes   Yes           
60 308302 50 M yes     yes       1y 12     yes yes yes             
61 308355 57 M         yes     2y 24     yes   yes             
62 308391 70 F   yes yes   yes     4y 48 yes       yes             
63 308411 58 M yes       yes yes   2y 24   yes   yes   yes       yes   
64 308420 55 M       yes       1y 12     yes   yes             
65 308578 60 F   yes     yes     2y 24     yes     yes           
66 308756 57 M yes     yes       4m 4     yes   yes             
67 308863 58 M       yes       3y 36     yes   yes             
68 308901 65 F         yes   Yes 6m 6   yes   yes     yes     yes   
69 308944 63 M yes yes   yes       2y 24   yes       yes           
70 308960 70 F         yes     5y 60   yes   yes     yes     yes   
71 308986 57 M   yes   yes       2y 24   yes     yes             
72 309008 34 M       yes       3m 3   yes   yes     yes         
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73 309156 60 M   yes   yes       1y 12 yes       yes             
74 309267 59 M yes       yes     1y 12     yes   yes             
75 309756 65 M    yes   yes       3y 36   yes       yes           
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